Skip to main content

Table 5 Univariate and multivariate analysis of prognostic factors related to overall survival after recurrence (n = 96)

From: Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions

Prognostic factor

Patients (n = 96)

Univariate analysis

Multivariate analysis

HR

95% CI

P-value

HR

95% CI

P-value

Menopausal status, n (%)

 pre-

44 (45.8)

1

     

 post-

52 (54.2)

1.396

0.891–2.186

0.145

  

Tumor size, n (%)

  ≤ 20 mm

17 (17.7)

1

     

  > 20 mm

77 (80.2)

1.317

0.726–2.388

0.364

  

 unknown

2 (2.1)

     

LN status, n (%)

 positive

63 (65.6)

1.309

0.829–2.066

0.248

   

 negative

33 (34.4)

1

    

Histological type, n (%)

 ductal

83 (86.5)

1

     

 speciala

13 (13.5)

1.028

0.543–1.945

0.932

  

LVI status, n (%)

 positive

63 (65.6)

1.287

0.769–2.156

0.337

   

 negative

25 (26.1)

1

    

 unknown

8 (8.3)

     

Operation status, n (%)

 partial mastectomy

17 (17.7)

1

     

 mastectomy

79 (82.3)

0.894

0.500–1.596

0.704

  

Chemotherapy, n (%)

 adjuvant

83 (86.5)

1.320

0.707–2.461

0.383

   

 none

13 (13.5)

1

    

Hormone therapy, n (%)

 adjuvant

50 (52.1)

0.719

0.460–1.122

0.146

   

 none

46 (47.9)

1

    

Primary ER status, n (%)

 positive

51 (53.1)

0.541

0.344–0.850

0.008*

0.724

0.382–1.372

0.322

 negative

45 (46.9)

1

     

Primary PR status, n (%)

 positive

47 (49.0)

0.595

0.380–0.931

0.023*

0.911

0.484–1.714

0.773

 negative

49 (51.0)

1

     

Primary HER2 status, n (%)

 positive

16 (16.7)

1.122

0.616–2.046

0.706

   

 negative

80 (83.3)

1

    

Primary Ki-67 expression, n (%)b

 high

55 (57.3)

1.848

1.170–2.917

0.008*

   

 low

41 (42.7)

1

    

Primary EZH2 expression, n (%)

 high

54 (56.3)

1.449

0.930–2.258

0.101

   

 low

42 (43.7)

1

    

Metastatic ER status, n (%)

 positive

41 (42.7)

0.972

0.625–1.513

0.901

   

 negative

55 (57.3)

1

    

Metastatic PR status, n (%)

 positive

39 (40.6)

0.692

0.440–1.089

0.112

   

 negative

57 (59.4)

1

    

Metastatic HER2 status, n (%)

 positive

14 (14.6)

1.282

0.673–2.440

0.450

   

 negative

82 (85.4)

1

    

Metastatic Ki-67 expression, n (%)b

 high

72 (75.0)

2.422

1.394–4.206

0.002*

   

 low

24 (25.0)

1

    

Metastatic EZH2 expression, n (%)

 high

59 (77.6)

2.116

1.143–3.916

0.017*

2.047

1.074–3.902

0.029*

 low

17 (22.4)

1

     

Metastatic sites, n (%)

 bones

24 (25.0)

0.899

0.548–1.476

0.674

   

 others

72 (75.0)

1

    

Disease free interval

  ≤ 2 years

28 (29.0)

1.713

1.086–2.702

0.021*

1.601

0.978–2.621

0.061

  > 2 years

68 (71.0)

1

     

  ≤ 10 years

83 (87.0)

1

    

  > 10 years

13 (13.0)

0.861

0.442–1.679

0.661

  
  1. Abbreviations: CI confidence interval, ER estrogen receptor, EZH2 enhancer of zeste homolog 2, HER2 human epidermal growth factor receptor 2, HR hazard ratio, LN lymph node, LVI lymphovascular invasion, PR progesterone receptor
  2. aSpecial type is invasive breast carcinoma except invasive ductal carcinoma
  3. bKi-67 expression was excluded from the multivariate analysis because of an association with EZH2 expression in primary and metastatic breast cancer lesions
  4. *Indicates values that are statistically significant (P < 0.05)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us